About us
MEG Maps™
Insights & Education
Patients
Find a MEG site
- Global
- North America
Contact us
🇨🇳

Select Page

MEGIN Spotlights

MEGIN Spotlight – MEG Epilepsy Case Studies

MEG Epilepsy Case Studies reviewing improved clinical outcomes using MEG presurgical mapping

Return To MEGIN Spotlights

Home
About us
MEG Maps™
Careers
Contact us
Join Our Mailing List

Insights & education
News
MEGIN Spotlights
MEGIN Masterclass
Abstracts & studies

Find a MEG site
Global
North America

Connect with us

Copyright 2025© – MEGIN
MEGIN’s new platform MEG Maps™ is powered by TRIUX™ neo and MEGreview™, which have 510(k) clearance from the US Food & Drug Administration (FDA) and are under EU MDR Notified body review, i.e. not available for commercial distribution in the EU area. For commercial distribution, please contact your local MEGIN representative. TRIUX™ neo is intended to non-invasively record brain activity, and when interpreted by trained physicians, to help localize these active areas. All other applications are scientific research in nature. Caution: Federal law (USA) restricts this device to sale by or on the order of a physician.

Subscribe to MEGIN Matters

Don’t miss the latest MEG insights and MEGIN news – complete the form below to be added to our mailing list and receive MEGIN Matters right in your inbox!